Johnson & Johnson announced a more than $1 billion investment in a next generation cell therapy facility in Montgomery County, Pennsylvania, expanding the company’s U.S. manufacturing capacity.
The new facility will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.
The announcement is part of the company’s previously unveiled $55 billion U.S. investment in manufacturing, R&D and technology through early 2029 and supports J&J’s plans to manufacture the vast majority of its advanced medicines in the U.S. to meet the needs of U.S. patients.
J&J, in partnership with Legend Biotech, currently markets the blockbuster multiple myeloma CAR-T cell therapy, Carvykti, first approved in early 2022.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!